http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03056011-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5c8c6c0264d81b8028879f33b1510d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da156916fc473dd5dd4f865836e148cd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2002-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d32c3cd997b7ede1c074f96b4eb8f28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58cbcf80f87dd0c6a777cc2e9e3de29c |
| publicationDate | 2003-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-03056011-A2 |
| titleOfInvention | Therapeuticum and prophylacticum for malignant diseases using phenotype suppression |
| abstract | The invention relates to therapeutic and prophylactic agents for malignant diseases based on phenotype suppression induced by a ds-oligoribonucleotide and/or dsm-RNA or a dsm-RNA fragment, in addition to a method for producing said agents, for testing and monitoring its effects and for selecting and screening novel medicaments. According to the invention, at least one of the phenotypically manifested properties is suppressed and the malignant cells or the malignant tumours are not necessarily killed or eliminated, but are returned to a benign state. The ds-oligoribonucleotide and/or the dsm-RNA or the dsm-RNA fragment, which complement a specific sequence of the gene that is activated with the completion of the malignant process in the cell and whose peptide products are responsible for the selection and the intracellular and transmembrane movement of the transcripts of at least one gene among the genes that are active or have been activated in the malignant cells, are used at least periodically as a universal therapeuticum or prophylacticum on patients with malignant cells or tumours, or on persons with an increased risk of developing cancer. The ds-oligoribonucleotide and/or the dsm-RNA or the dsm-RNA fragment are produced on their own or in a combination of at least two of the above, which complement one of the gene-specific sequences of at least one gene among the genes that contribute directly or indirectly to the malignant process, irrespective of whether said genes also occur in normal cells or are responsible for the high risk of developing cancer. The production is carried out by in vitro synthesis, in defined length and symmetry. |
| priorityDate | 2001-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.